Brief: Denali Therapeutics Q3 Operating Expenses USD 137.434 Million
06/11/2025 21:01
Nov 06 (Reuters) - Denali Therapeutics Q3 operating income USD -137.434 million. Q3 basic EPS USD -0.74 Q3 net income USD -126.902 million
Recent news on Denali Therapeutics
See all newsDenali Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Denali Therapeutics Q2 net loss widens as AVLAYAH launch costs rise
Biogen's Alzheimer's drug lowers toxic protein, but results were mixed
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive
U.S. STOCKS ON THE MOVE-IMAX, Novo Nordisk, PC makers